{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:38:45Z","timestamp":1790293125317,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T00:00:00Z","timestamp":1434931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mahnaz Asgharnejad"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2015,10]]},"abstract":"Background and purpose<\/jats:title>Non\u2010motor symptoms (NMS<\/jats:styled-content>) of Parkinson's disease (PD<\/jats:styled-content>) have a major impact on health\u2010related quality of life. This is the first randomized controlled trial to use the NMS<\/jats:styled-content> Scale (NMSS<\/jats:styled-content>) as a primary outcome to assess treatment effects on NMS<\/jats:styled-content> in PD<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>In this double\u2010blind trial (NCT<\/jats:styled-content>01300819), patients with PD<\/jats:styled-content> and a total NMSS<\/jats:styled-content> score \u226540 were randomized (2:1) to rotigotine or placebo, titrated over 1\u20137\u00a0weeks to optimal dose (\u22648\u00a0mg\/24\u00a0h for patients not receiving levodopa, \u226416\u00a0mg\/24\u00a0h for patients receiving levodopa), maintained for 12\u00a0weeks. The primary outcome was change in NMSS<\/jats:styled-content> total score from baseline to end of maintenance. Secondary outcomes were the nine NMSS<\/jats:styled-content> domains, Unified Parkinson's Disease Rating Scale (UPDRS<\/jats:styled-content>) III<\/jats:styled-content> (motor) and the 39\u2010item Parkinson's Disease Questionnaire (PDQ<\/jats:styled-content>\u201039).<\/jats:p><\/jats:sec>Results<\/jats:title>In total, 283\/349 (81.1%) randomized patients completed the trial; 211 rotigotine and 122 placebo were included in the full analysis set. The NMSS<\/jats:styled-content> total score decreased by 23 (rotigotine) and 19 (placebo) points; the treatment difference was not statistically significant (\u22123.58; 95% confidence interval \u22128.43, 1.26; P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.147). Numerically greater than placebo improvements were detected in the \u2018mood\/apathy\u2019 and \u2018miscellaneous\u2019 NMSS<\/jats:styled-content> domains (P\u00a0<\/jats:italic><\u00a0<\/jats:italic>0.05). Treatment differences in UPDRS III<\/jats:styled-content> (\u22122.60; \u22124.27, \u22120.92; P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.002) and PDQ<\/jats:styled-content>\u201039 (\u22122.79; \u22125.21, \u22120.37; P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.024) favoured rotigotine. Adverse events reported more frequently with rotigotine were nausea, application site reactions, somnolence and headache.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Rotigotine improvement in the multi\u2010domain NMSS<\/jats:styled-content> total score was not superior to placebo. A different sensitivity of individual NMSS<\/jats:styled-content> domains to dopaminergic therapy and a large placebo effect may have contributed to these findings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.12757","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T05:29:15Z","timestamp":1434950955000},"page":"1400-1407","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non\u2010motor symptoms \u2013 results of a double\u2010blind, randomized, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"22","author":[{"given":"A.","family":"Antonini","sequence":"first","affiliation":[{"name":"Parkinson and Movement Disorders Unit IRCCS Hospital San Camillo Venice Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bauer","sequence":"additional","affiliation":[{"name":"UCB Pharma Monheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dohin","sequence":"additional","affiliation":[{"name":"UCB Pharma Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H.","family":"Oertel","sequence":"additional","affiliation":[{"name":"Department of Neurology Philipps University Marburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Rascol","sequence":"additional","affiliation":[{"name":"Clinical Investigation Centre CIC1436 and Departments of Clinical Pharmacology and Neurosciences INSERM and Toulouse University Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Reichmann","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Dresden Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmid","sequence":"additional","affiliation":[{"name":"UCB Pharma Monheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Singh","sequence":"additional","affiliation":[{"name":"UCB Pharma Monheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tolosa","sequence":"additional","affiliation":[{"name":"Neurology Service Hospital Clinic de Barcelona Universitat de Barcelona IDIBAPS Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Barcelona Catalonia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"National Parkinson Foundation International Centre of Excellence King's College Hospital Kings College and Kings Health Partners London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70068-7"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.02.018"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12523"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22643"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23462"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22868"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(01)00015-3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318285c16d"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318285c0ed"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20844"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c0d416"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21596"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23826"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"11 e2","DOI":"10.1136\/jnnp-2013-306573.166","article-title":"Are there non\u2010motor symptoms specific to Parkinson's disease?","volume":"84","author":"Steiger M","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23441"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70106-X"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2011-11037"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3182613dea"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26067"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.12.012"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.12757","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.12757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:25:02Z","timestamp":1695551102000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.12757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,22]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/ene.12757"],"URL":"https:\/\/doi.org\/10.1111\/ene.12757","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,22]]},"assertion":[{"value":"2014-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}